Scancell (LON:SCLP) Posts Quarterly Earnings Results

Scancell (LON:SCLP) posted its quarterly earnings data on Thursday. The company reported GBX (1.35) (($0.02)) EPS for the quarter, Digital Look Earnings reports.

Scancell Stock Performance

Shares of LON SCLP opened at GBX 9.40 ($0.12) on Friday. The company has a 50-day simple moving average of GBX 10.84 and a 200-day simple moving average of GBX 13.63. The company has a debt-to-equity ratio of 61.41, a current ratio of 3.42 and a quick ratio of 13.01. The company has a market cap of £87.38 million, a PE ratio of -940.00 and a beta of 0.35. Scancell has a 12 month low of GBX 8.60 ($0.11) and a 12 month high of GBX 19.75 ($0.24).

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.